Canada

Resverlogix Corp

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study

Lead Product(s): Apabetalone,Atorvastatin

Therapeutic Area: Endocrinology Product Name: RVX000222

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

The FDA has accepted Resverlogix BETonMACE2 clinical plan as a registration enabling study with positive implications for Resverlogix and its ongoing partnership discussions.

Resverlogix Corp

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual Congress

Lead Product(s): Apabetalone,Atorvastatin

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 09, 2020

Details:

For the first time in patients with a recent Acute Coronary Syndrome with diabetes and stage 3 CKD co-morbidities, we observed a 50% reduction of MACE by a medication, apabetalone treatment.

Resverlogix Corp

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association

Lead Product(s): Apabetalone,Atorvastatin

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2020

Details:

Apabetalone recently completed the first ever Phase 3 clinical trial of a BET inhibitor for a cardiovascular disease indication.

Resverlogix Corp

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Resverlogix Receives FDA Breakthrough Therapy for Apabetalone

Lead Product(s): Apabetalone

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 03, 2020

Details:

FDA has granted Breakthrough Therapy Designation for apabetalone in combination with high-intensity statins, for the secondary prevention of MACE in patients with type 2 DM and recent ACS.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Resverlogix Corp

Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study

Resverlogix Corp

Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual Congress

Resverlogix Corp

Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association

Resverlogix Corp

Resverlogix Receives FDA Breakthrough Therapy for Apabetalone